December 10, 2019 Non Regulatory LIDDS: Update of News Release sent on November 9, 2019, with PDF-file: New Company Update and Market Valuation from Redeye
December 2, 2019 Non Regulatory LIDDS Interview with the LPC-004 study investigator, Professor Laurence Klotz, about the LIDDS Liproca® Depot Phase IIb study results
November 16, 2019 Regulatory LIDDS Liproca® Depot Phase IIb study results presented at EMUC19 showing both primary and secondary endpoints being met
November 7, 2019 Regulatory LIDDS licensee Jiangxi Puheng Pharma prepares for phase III trial in China
October 23, 2019 Regulatory LIDDS: Liproca® Depot open label extension study indicates PSA reduction for up to one year
September 24, 2019 Non Regulatory LIDDS: Wikow Invest is still the biggest shareholder in LIDDS (publ)
September 24, 2019 Regulatory Preliminary results from Phase IIb Liproca® Depot dose-finding study show a strong maximum PSA decrease and sustained PSA reduction effect
August 28, 2019 Non Regulatory LIDDS: Liproca® Depot Phase IIb results to be presented as “Late Breaking News” at EMUC in Vienna on November 16, 2019
May 6, 2019 Regulatory LIDDS: Liproca® Depot open label extension study indicates longer treatment intervals
May 2, 2019 Regulatory LIDDS develops its own proprietary product for intratumoral immunotherapy – Freedom to operate analysis done for the TLR9-agonist project
April 2, 2019 Regulatory LIDDS announces a novel TLR9 agonist project and plan for Phase I clinical trial
March 18, 2019 Regulatory LIDDS to evaluate a possible listing of the company’s shares on Nasdaq Stockholm’s Main Market during 2020
March 13, 2019 Non Regulatory LIDDS: First patient receives intratumoral NanoZolid®-docetaxel in Phase I study
March 6, 2019 Non Regulatory LIDDS: Final patient enrolled in Phase IIb Liproca® Depot prostate cancer study
February 5, 2019 Non Regulatory LIDDS adds another Scandinavian clinic to the NZ-DTX-001 clinical trial
February 4, 2019 Non Regulatory LIDDS research activities in intratumoral immunotherapy are in line with leading oncology expert recommendations